Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2855-2859

  Espinel Ingroff, A ^a   Fothergill, A ^b   Fuller, J ^c   Johnson, E ^d   Pelaez, T ^e   Turnidge, J ^f  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; TRIAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; BROTH DILUTION; CANADA; CONTROLLED STUDY; DRUG CONCENTRATION; EPIDEMIOLOGIC CUTOFF VALUE; EUROPE; MINIMAL EFFECTIVE CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; UNITED STATES; WILD TYPE;

ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS;

EID: 79956307891     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01730-10     Document Type: Article

References (32)

1. Alcazar-Fuoli, L., E. Mellado, A. Alastruey-Izquierdo, M. Cuenca-Estrella, and J. L. Rodríguez-Tudela. 2009. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob. Agents Chemother. 53:4514-4517.
2. Arendrup, M. C., et al. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implications for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.
3. Arendrup, M. C., et al. 2008. Establishing in vitro-in vivo correlations of Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob. Agents Chemother. 52:3504-3511.
4. Barnes, P. D., and K. A. Marr. 2007. Risk, diagnosis and outcome of invasive fungal infections in haematopoietic stem cell transplant recipients. Br. J. Haematol. 139:519-531.
5. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FSK1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed.; approved standard. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2010. Method for antifungal disk diffusion susceptibility testing of non-dermatophyte fungi; approved standard. CLSI document M51-A. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Dalhoff, A., P. G. Ambrose, and J. W. Mouton. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305.
9. Denning, D. W. 2006. Aspergillus and aspergillosis - progress on many fronts. Med. Mycol. 44:S1-S2.
10. Desnos-Ollivier, M., et al. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
11. Eschertzhuber, S., C. Velik-Salchner, C. Hoefer, and C. Lass-Florl. 2008. Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transpl. Infect. Dis. 10:190-192.
12. Espinel-Ingroff, A., et al. 2001. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob. Agents Chemother. 45:1828-1835.
13. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by the NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
14. Espinel-Ingroff, A. 2003. Evaluation of microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41:403-409. (Pubitemid 36098607)
15. Espinel-Ingroff, A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2). J. Clin. Microbiol. 48:3251-3257.
16. Fuller, J., et al. 2010. Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration. J. Clin. Microbiol. 48:479-482.
17. Garcia-Effron, G., S. Lee, S. Park, J. D. Cleary, and D. S. Perlin. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
18. Garcia-Effron, G., S. Park, and D. S. Perlin. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
19. Gardiner, R. E., P. Souteropoulos, S. Park, and D. S. Perlin. 2005. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Mycoses 43:S299-S305.
20. Lass-Flörl, C., A. Alastruey-Izquierdo, M. Cuenca-Estrella, S. Perkhofer, and J. L. Rodríguez-Tudela. 2009. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:794-795.
21. Madureira, A., et al. 2007. Breakthrough invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients treated with caspofungin. Int. J. Antimicrob. Agents 30:551-554.
22. Odds, F. C., et al. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
23. Pfaller, M. A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
24. Pfaller, M. A., et al. 2009. Wild type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
25. Pfaller, M. A., et al. 2010. Wild-type minimum effective concentration and epidemiological cutoff values for caspofungin and Aspergillus spp. MIC distributions as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. Diagn. Microbiol. Infect. Dis. 67:56-60.
26. Pfeiffer, C. D., et al. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380.
27. Rocha, E. M. F., G. Garcia-Effron, S. Park, and D. S. Perlin. 2007. A Ser678pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 51:4174-4176.
28. Thompson, G. R., et al. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.
29. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
30. Turnidge, J., and D. L. Patterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408.
31. Walker, L. A., N. A. Gow, and C. A. Munro. 2010. Fungal echinocandin resistance. Fungal Genet. Biol. 47(2):117-126.
32. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.